Parkinson's Disease - Review of Key Commercial Opportunities in the Symptomatic Treatment Market

Parkinson's disease (PD) is a progressive, degenerative condition of the central nervous system (CNS), caused by the degeneration of dopaminergic neurons in the substantia nigra of the midbrain. The PD market grew by 6.9% to $1.8 billion between 2004 and 2005. In the absence of conclusive evidence for a neuroprotective compound, the focus on the market remains on symptomatic treatment.

Scope

> Assessment of patient size across the seven major markets (US, Japan, France, Germany, Italy, Spain, UK) including prevalence of co-morbid conditions.

> Overview of Parkinson's disease market dynamics, discussing market share across the seven major markets, drug classes and brands.

> Qualitative interviews with key international opinion leaders.

> Case study analysis of new market entrants which target different disease stages, leading to recommendations to companies entering the market.

Report Highlights

> Manufacturers of neuroprotective products will benefit from driving research and awareness of new diagnostic technologies such as genetic testing to better identify patients in the very early stages of PD or those at risk of the disease.

> Companies developing improved delivery technologies including continuous transdermal dopamine agonist stimulation and smooth delivery of levodopa will be at a competitive advantage and that novel formulations will become an increasingly important product differentiating strategy.

> The major unmet need in the treatment in advanced PD is the reduction of OFF periods. Few companies have investigated this area since advanced patient opportunities represent a very small market and Vernalis' Apokyn (apomorphine) is presently the only drug available for this specific use.

Reasons to Purchase

> Understand key opinion leaders (KOL) views on hot issues in Parkinson's disease diagnosis, treatment, and unmet needs.

> Identify the opportunities and threats for Azilect (rasagiline), Neupro (rotigotine CDS), and Apokyn (apomorphine) in the market.

> Identify future challenges to Parkinson's disease drugs and best method of overcoming these.

25-Jul-06 PDF + Slidepack Pages: 105
Table of Contents
Price: $3,800.00 / GBP1,976.00